Shots:
- Incyte will lead the development, manufacture, and supply of both products. ST will be responsible for the regulatory, distribution, and local marketing related activities in Australia, New Zealand & Singapore
- Tafasitamab + lenalidomide is approved in the US & EU to treat adult patients with r/r DLBCL who are not eligible for ASCT
- Pemigatinib is approved in the US, EU & Japan to treat LA or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that has progressed after one prior line of systemic therapy. In Jan’20, Incyte has entered into a collaboration and license agreement with MorphoSys to develop and commercialize tafasitamab globally
Click here to read full press release/ article | Ref: PRNewswire | Image: ECIJA
The post Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries first appeared on PharmaShots.
